FDA, EMA Valsartan Update, New Data on Cancer Risk

10:45 EDT 13 Sep 2018 | Medscape

The FDA and EMA report a possible second carcinogen in previously withdrawn vasartan products, while a new analysis finds no increased cancer risk in those who previously took contaminated valsartan.
Medscape Medical News

Original Article: FDA, EMA Valsartan Update, New Data on Cancer Risk


More From BioPortfolio on "FDA, EMA Valsartan Update, New Data on Cancer Risk"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...